IDWeek 2024

IDWeek 2024
October 16-20, 2024
US - Los Angeles, CA

Infectious Diseases Society of America: ID Week 2024.

Explore more information for Gilead HIV / AIDS therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (19)

    Update on Lenacapavir for PrEP: Results From the Interim Analyses of PURPOSE 1 and PURPOSE 2

    • Author(s): Kelley, C
    • sunlenca
    • descovy-for-prep
    • truvada-for-prep
    • HIV / AIDS

    Long-Acting Subcutaneous Lenacapavir in People with Multi-Drug Resistant HIV-1: 3-Year Results of the Capella Study

    • Author(s): Onyema, O
    • sunlenca
    • HIV / AIDS

    Impact of Pharmacoenhancers on the Pharmacokinetics and Safety of Lenacapavir in People with HIV

    • Author(s): Jogiraju, V
    • sunlenca
    • HIV / AIDS

    Thorough QT/QTc Clinical Study to Evaluate the Effect of Remdesivir on Cardiac Repolarization in Healthy Male and Female Participants

    • Author(s): Anoshchenko, O
    • remdesivir
    • COVID-19

    Resistance Analyses from the Remdesivir Phase 2/3 CARAVAN Study in Pediatric and Neonatal Participants Hospitalized with COVID-19

    • Author(s): Moshiri, J
    • remdesivir
    • COVID-19

    Combination therapy with remdesivir and corticosteroids is associated with lower mortality risk vs. corticosteroids monotherapy in patients hospitalised for COVID-19

    • Author(s): Mozaffari, E
    • remdesivir
    • COVID-19

    Obeldesivir for Treatment of COVID-19 in Adults and Adolescents Without Risk Factors for Progression to Severe Disease: The OAKTREE Study

    • Author(s): Ogbuagu, O
    • obeldesivir
    • COVID-19

    Coming Soon!

    • Author(s): Gilead
    • biktarvy
    • HIV / AIDS
    • Poster

    Predictors of Undetectable HDV RNA 48 Weeks After Completion of Finite Treatment With Bulevirtide And Pegylated-Interferon Alpha 2A

    • Author(s): Bogomolov, P
    • bulevirtide
    • Liver Diseases

    Obeldesivir reduced SARS-CoV-2 infectious titers in the BIRCH Phase 3 Clinical Trial

    • Author(s): Rodriguez, L
    • obeldesivir
    • COVID-19

    Efficacy and Safety of B/F/TAF in Treatment-Naive People with HIV Aged ≥ 50 Years: 5-Year Follow-up from Two Phase 3 Sutdies

    • Author(s): Kityo, C
    • biktarvy
    • HIV / AIDS

    Efficacy and Safety of B/F/TAF in Black Adults with HIV who are Treatment-Naive: 5-Year Follow-up from Two Phase 3 Studies

    • Author(s): Wurapa, K
    • biktarvy
    • HIV / AIDS

    Trajectories of Newly Initiated Pre-Exposure Prophylaxis Use among Priority Populations with Unmet Needs for PrEP in the USA

    • Author(s): Tao, L
    • truvada-for-prep
    • descovy-for-prep
    • HIV / AIDS

    Changes in Renal Function After Switching from Emtricitabine/Tenofovir Disoproxil Fumarate to Emtricitabine/Tenofovir Alafenamide Fumarate for HIV Pre exposure Prophylaxis (PrEP): A Real-World Study

    • Author(s): Ito, K
    • truvada-for-prep
    • descovy-for-prep
    • HIV / AIDS

    Efficacy And Safety Of Bulevirtide Monotherapy For Chronic Hepatitis D In Patients With And Without Cirrhosis: Results From The Week 144 Interim Analysis Of A Phase 3 Randomized Study

    • Author(s): Aleman, S
    • bulevirtide
    • Liver Diseases

    How Have COVID-19 Treatment Guidelines And The Scientific Evidence Evolved Throughout The Pandemic And Endemic Eras?

    • Author(s): Mozaffari, E
    • remdesivir
    • COVID-19

    Patient Characteristics and Management of COVID-19 Diagnosed in the Outpatient Setting

    • Author(s): Berry, M
    • remdesivir
    • COVID-19

    Characteristics, clinical management, and outcomes of Leukemia, Lymphoma and Multiple Myeloma patients hospitalized with a primary diagnosis of COVID-19: Insights from hospitals across the United States

    • Author(s): Mozaffari, E
    • remdesivir
    • COVID-19

    Obeldesivir for the Treatment of COVID-19 in People With Risk Factors for Progression to Severe Disease: The BIRCH Study

    • Author(s): Streinu-Cercel, A
    • obeldesivir
    • COVID-19